467 related articles for article (PubMed ID: 18006614)
61. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ
J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613
[TBL] [Abstract][Full Text] [Related]
62. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
63. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
64. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
[TBL] [Abstract][Full Text] [Related]
65. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.
Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL
Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224
[TBL] [Abstract][Full Text] [Related]
66. PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy.
Saga T; Koizumi M; Inubushi M; Yoshikawa K; Tanimoto K; Fukumura T; Miyamoto T; Nakajima M; Yamamoto N; Baba M
Nucl Med Commun; 2011 May; 32(5):348-55. PubMed ID: 21326122
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer.
Yoshioka T; Yamaguchi K; Kubota K; Saginoya T; Yamazaki T; Ido T; Yamaura G; Takahashi H; Fukuda H; Kanamaru R
J Nucl Med; 2003 May; 44(5):690-9. PubMed ID: 12732669
[TBL] [Abstract][Full Text] [Related]
68. [18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.
Anton-Rodriguez JM; Lewis D; Djoukhadar I; Russell D; Julyan P; Coope D; King AT; Lloyd SKL; Evans DG; Jackson A; Matthews JC
Otol Neurotol; 2019 Jul; 40(6):826-835. PubMed ID: 31033921
[TBL] [Abstract][Full Text] [Related]
69.
Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
[TBL] [Abstract][Full Text] [Related]
70. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
71. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer.
von Forstner C; Egberts JH; Ammerpohl O; Niedzielska D; Buchert R; Mikecz P; Schumacher U; Peldschus K; Adam G; Pilarsky C; Grutzmann R; Kalthoff H; Henze E; Brenner W
J Nucl Med; 2008 Aug; 49(8):1362-70. PubMed ID: 18632830
[TBL] [Abstract][Full Text] [Related]
72. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.
Linecker A; Kermer C; Sulzbacher I; Angelberger P; Kletter K; Dudczak R; Ewers R; Becherer A
Nuklearmedizin; 2008; 47(2):80-5; quiz N12. PubMed ID: 18392317
[TBL] [Abstract][Full Text] [Related]
73. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
74.
Christensen TN; Langer SW; Persson G; Larsen KR; Loft A; Amtoft AG; Berthelsen AK; Johannesen HH; Keller SH; Kjaer A; Fischer BM
J Nucl Med; 2021 May; 62(5):628-635. PubMed ID: 33037090
[TBL] [Abstract][Full Text] [Related]
75. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
Chen R; Zhou X; Liu J; Huang G
J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
[TBL] [Abstract][Full Text] [Related]
76. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000
[TBL] [Abstract][Full Text] [Related]
77. Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT.
Cohade C; Osman M; Pannu HK; Wahl RL
J Nucl Med; 2003 Feb; 44(2):170-6. PubMed ID: 12571205
[TBL] [Abstract][Full Text] [Related]
78. Comparison of semiquantitative metabolic parameters of the primary tumor obtained in PET/CT with 18F-FDG and 18F-FLT in patients with cervical cancer.
Cegła P; Burchardt E; Cholewiński W; Gwóźdź S; Roszak A; Kubiak A; Kaczmarek A; Czepczyński R
Nuklearmedizin; 2020 Jun; 59(3):241-247. PubMed ID: 32097971
[TBL] [Abstract][Full Text] [Related]
79. Clinical relevance of imaging proliferative activity in lung nodules.
Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526
[TBL] [Abstract][Full Text] [Related]
80. Prediction of tumor biological characteristics in different colorectal cancer liver metastasis animal models using
Xu HL; Li M; Zhang RJ; Jiang HJ; Zhang MY; Li X; Wang YQ; Pan WB
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):140-148. PubMed ID: 29571649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
